TAK-653
Treatment-Resistant Depression
Key Facts
About Thermo Fisher Scientific
Thermo Fisher Scientific's mission is to enable its customers to make the world healthier, cleaner, and safer by providing the scientific tools and services that accelerate innovation. The company has achieved a dominant market position through strategic acquisitions, organic innovation, and the creation of an unparalleled, integrated ecosystem for the scientific community. Its strategy revolves around leveraging its scale and breadth to drive operational excellence, investing in high-growth areas like bioproduction and precision medicine, and selectively advancing an internal pipeline of novel therapeutics. With a market capitalization exceeding $178 billion, Thermo Fisher is a foundational pillar of the global life sciences industry.
View full company profileTherapeutic Areas
Other Treatment-Resistant Depression Drugs
| Drug | Company | Phase |
|---|---|---|
| DB104 (Liafensine) | Denovo Biopharma | Phase 2b |
| VNS Therapy for TRD | LivaNova | PMA Supplement |
| Precision Radiomodulation Research | ZAP Surgical | Feasibility Study |
| NOE-101 (basimglurant) | Noema Pharma | Phase 2b |
| PCN-101 (R-ketamine) | Perception Neuroscience | Phase 2a |
| mGlu2 NAM Program for TRD | Camino Pharma | Pre-clinical |
| SPN-820/821 | Supernus Pharmaceuticals | Phase 3 |
| BPL-003 | atai Life Sciences | Phase 2 |
| VLS-01 | atai Life Sciences | Phase 2 |